We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Reneuron Group Plc | LSE:RENE | London | Ordinary Share | GB00BF5G6K95 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.05 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 530k | -5.41M | -0.0946 | -0.32 | 1.74M |
Date | Subject | Author | Discuss |
---|---|---|---|
11/7/2018 21:23 | So what , Tell Sid ! Lots of us are holding from...for ever it seems. | dogwalker | |
11/7/2018 15:50 | Still holding some from last year. | tell sid | |
11/7/2018 14:06 | ww, they have had many opportunities outside of results to buy shares. ok, so they might not be amazingly well paid academic types but still, if i knew what they knew i would still buy. but my gut feeling with the bod is that they are more interested in the science of it all. so fine, if they get that bit right i dont really care the share price will look after itself. one question for someone above that quoted the global sales of the retina and stroke products. are those figures truly attributable on a licensing deal or what % would rene actually get for licensing out, which is usually the preferred route for this size of company ? | martinfrench | |
11/7/2018 13:53 | Martinfrench - I agree that would be a positive, but absence is not necessarily a negative.1) they will be under NDA which will make it difficult to buy shares.2) hvo has tripled - another Woodford bomb - but no sign of director buying there either, from memory.So pmdr purchases are unlikely at this stage, but certainly not a prerequisite for a major rerating anyway, imo. | wigwammer | |
11/7/2018 13:42 | what we do also need which has been absent from rene from day 1 is some director buying, if results are fairly clear now until hitting some sort of mkt. i'm a lth btw..... | martinfrench | |
11/7/2018 13:38 | Yes gersemi, RENE has pretty exciting potential. Worth listening to the proactive interview earlier - from memory the term used was "grossly undervalued". I suspect the reason it is under the radar of most pi's is that the institutional ownership appears very high. Woodford alone owns 35%, but there are several other large institutions on the register. So there are little in free float to get pi's interested. Of course, it doesn't hurt to have deep pocketed institutional backers, but it does mean the shares likely react to news more slowly as the more liquid sources digest the news. HVO is a similar case - high institutional ownership, and post its recent positive product news it sat at 25p for hours before the market woke up. It's now 70p+. Hang in there - tomorrow may be interesting - there will be evidence of further cash burn but perhaps more detail on the exclusivity deal - I'm a happy holder for the medium term. | wigwammer | |
11/7/2018 13:29 | Dangerous bubble. | ken chung | |
11/7/2018 13:15 | Yes wigwammer, I don't doubt you're correct fella but the cash does provide that solidity and removes the threat of the dreaded placing that tends to haunt smaller bio-pharma stocks I never noticed this stock before - myopic to say the least exciting stuff though investing isn't supposed to be 'exciting' | gersemi | |
11/7/2018 13:12 | Don't tell Rocket man that as apparently the cash means nothing | jon1962 | |
11/7/2018 13:11 | I don't think this is a "cash story" tbh. They will spend the cash, and I have little doubt that after the results tomorrow the dullwits will be reminding us about cash burn. The point is the £200m+ has been spent progressing the assets, and these assets are now reaching a point where their value can be monetised. The RNS today could prove pivotal. Third parties do not depart with millions of dollars unless they are taking the potential seriously. Given the current market cap of RENE is £32m, a fraction of what has been invested here, it doesn't require a great deal of imagination to see the needle could now move considerably in the right direction ie multibag. The potential perceived by the market historically now appears to be on the verge of realisation. Good stuff :) | wigwammer | |
11/7/2018 13:01 | Yes algernon2, it's worth doing a bit of digging to find out the identity - i hope this does do an 'OXB' - sat on a good profit with OXB and stil holding I love the cash here - supports the equity value considerably | gersemi | |
11/7/2018 12:40 | fair enough. | algernon2 | |
11/7/2018 12:39 | I would suspect someone a bit more established, but with no good reason! | small crow | |
11/7/2018 12:38 | Any one willing to speculate on who is paying us this fee for 3 months "exclusivity" in which to do their Due Diligance? I will start with a wild stab and say Axovant (because of their 2 recent acquisitions: one with Oxford Biomedica and one with Benitec. They are heavily on the acquisition trail to build up their portfolios as they admit. Any one else want a guess.No prizes for accuracy just kudos if you are right. Only one guess per avatar allowed. | algernon2 | |
11/7/2018 12:15 | Will be if you keep posting Kenneth! | small crow | |
11/7/2018 12:09 | Painful times ahead. | ken chung | |
11/7/2018 12:09 | Many people feeding the bubble. | ken chung | |
11/7/2018 11:47 | ReNeuron surges on stem cell agreement with US pharma group | johnwise | |
11/7/2018 11:21 | Rocket fuel - a few years ago, I would have agreed with you. Two things have changed:1) the share price/valuation has fallen dramatically2) the drugs have progressed through the clinic...I'm up circa 40% here on my average entry price and suspect it's going a lot higher. You keep up the good work on that ph though and try and keep up :) | wigwammer | |
11/7/2018 11:00 | I can almost feel the sweat poring off your brow mate knowing about the future prospects of this company.Interesting you won't explain your presence here.No sane person wastes time on a share they have no interest in owning unless of course they have an obvious agenda that you have.I take it you are not yet mentally insane so the above must be true.I will not be wasting my time replying to you again.We all know why you are here | jon1962 | |
11/7/2018 10:59 | Anyone interested take a look at the company presentation from may 2018. . | greedfear | |
11/7/2018 10:58 | Added today. Trading below cash per share. Partnering/outlicens Pipeline with possible peak sales of $0.5-$1.6 billion for hRPC for RP and $1.1-$2.2 CTX for stroke (+ value of exosomes ????). Let's take the minimum, $1.6 billion in total. Big Pharma will pay something like 3x peak sales. That will be $4.8 billion (+value of exosomes ??). All that for nothing, as trading below cash per share. . | greedfear | |
11/7/2018 10:54 | Took a position today for two reasons: market cap covered significantly by cash deals to come OXB and RENE are my biopharma 'punts'! | gersemi |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions